Will the FDA approve camizestrant for advanced breast cancer?
Price history — Before Jan 1, 2028
Last 7 days of market YES price (blue) with the fair-price range (orange).
━ market YES▬ fair range
Market price
71¢
59¢
41¢
31¢
7¢
Kalshi • Volume: 3.2K contracts • Updated 4h agoCloses: 2028-01-01
Kalshi · Science and Technology
OU's Pick
YES · Before Jan 1, 2028
at 71¢
Price gap
Kalshi71¢
→OU's fair15¢
−56¢ overpriced · pays 1.4×
Confidence
High
The FDA Oncologic Drugs Advisory Committee voted against the clinical benefit of camizestrant on April 30 2026 which significantly reduces the likelihood of near-term approval.
Wide edge+56¢
High conviction
Not financial advice. For informational purposes only. Prediction markets involve risk of loss. AI may contain errors.